Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | INCA33890 |
Synonyms | |
Therapy Description |
INCA33890 is a bispecific antibody targeting PDCD1 (PD-1) and TGFBR2, which potentially induces cytokine production and inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 2936). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INCA33890 | INCA-33890|INCA 33890 | PD-L1/PD-1 antibody 122 TGFBR2 Antibody 3 | INCA33890 is a bispecific antibody targeting PDCD1 (PD-1) and TGFBR2, which potentially induces cytokine production and inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 2936). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05836324 | Phase I | INCA33890 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | CHE | 1 |